Previous 10 | Next 10 |
Summary Davis Selected Advisers 13F portfolio value decreased from $15.59B to $14.06B this quarter. They increased Meta Platforms and Teck Resources while reducing Intel, Loews, and Alibaba Group Holding. The top three positions are Wells Fargo, Berkshire Hathaway, and Capital...
The U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) on Thursday announced insider trading charges against Ramkumar Rayapureddy, the chief information officer of generic drugmaker Viatris ( NASDAQ: VTRS ). The SEC and DOJ alleged that from 20...
TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3 ’ 22 Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Profes...
Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent PR Newswire PITTSBURGH , Nov. 10, 2022 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P...
Dividend stocks are a good way to supplement your income. And while most of them don't pay monthly, you can still generate monthly income by investing in dividend stocks that have staggered payment schedules. Three stocks that provide high yields that are more than double the S&P 500 ...
Summary Viatris’ business is holding up better than expected, despite FX headwinds. A new path to growth clears visibility for investors as the company targets to be the next ophthalmology leader. In addition, the portion of shareholder rewards through dividends and buy...
The following slide deck was published by Viatris Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Viatris Inc. 2022 Q3 - Results - Earnings Call Presentation
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties Strengthened Financial Position Supports Operations and APX3330 Program into 2025 Conference Call Tomorrow November 8, 2022 a...
Viatris Inc. (VTRS) Q3 2022 Results Conference Call November 07, 2022 08:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Robert Coury - Executive Chairman Michael Goettler - Chief Executive Officer Rajiv Malik - President Dr...
Shares of Viatris (NASDAQ: VTRS) were jumping 16.2% higher as of 11:56 a.m. ET on Monday. The big gain came after the company announced its third-quarter results and revealed plans for two acquisitions. Viatris reported Q3 revenue of $4.08 billion. This result was down 10% year ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...